Onconetix, Inc. Overview
Pro stress-test →Onconetix is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products.
Strategic Profile
Pro stress-test →Onconetix is navigating significant operational challenges and capital constraints typical of early-stage biotech companies. The company executed a 1-for-5 reverse stock split in March 2026 to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. A subsequent 1-for-10 reverse stock split was approved in May 2026, again to comply with Nasdaq listing requirements.
Competitive Landscape
Pro stress-test →Onconetix competes in the prostate cancer diagnostics market with its Proclarix test. The broader competitive landscape includes established diagnostic companies and other cancer biomarker developers. The company's partnership with LabCorp provides distribution advantages but faces competition from multiple prostate cancer testing solutions already in clinical use.
Industry Context
Onconetix, Inc. operates in Biotechnology - In Vitro Diagnostics.
Key facts
Founded: 2018 · Headquarters: Cincinnati, Ohio · Employees: N/A · Revenue: N/A · Market cap: $83M